U.S. markets open in 3 hours 59 minutes

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.7700-0.0500 (-1.77%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.8200
Bid2.3100 x 800
Ask0.0000 x 1400
Day's Range2.7000 - 2.8163
52 Week Range1.1900 - 3.8900
Avg. Volume444,223
Market Cap182.51M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • What Kind Of Shareholders Own Chimerix, Inc. (NASDAQ:CMRX)?
    Simply Wall St.

    What Kind Of Shareholders Own Chimerix, Inc. (NASDAQ:CMRX)?

    If you want to know who really controls Chimerix, Inc. (NASDAQ:CMRX), then you'll have to look at the makeup of its...

  • Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates

    Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates

    Chimerix (CMRX) delivered earnings and revenue surprises of 11.11% and 19.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Recap: Chimerix Q2 Earnings

    Shares of Chimerix (NASDAQ:CMRX) were flat in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 54.29% year over year to ($0.16), which beat the estimate of ($0.17).Revenue of $1,402,000 declined by 2.50% from the same period last year, which beat the estimate of $1,060,000.Outlook Chimerix hasn't issued any earnings guidance for the time being.Chimerix hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Aug 10, 2020View more earnings on CMRXTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/f4xqp47nPrice Action 52-week high: $3.8852-week low: $1.19Price action over last quarter: Up 17.41%Company Overview Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes a treatment for acute myeloid leukemia (or AML) and an antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment--pharmaceuticals.See more from Benzinga * Recap: Momenta Pharmaceuticals Q2 Earnings * Recap: Amicus Therapeutics Q2 Earnings * Recap: Intercept Pharmaceuticals Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.